行情

PETX

PETX

Aratana
NASDAQ

实时行情|Nasdaq Last Sale

4.920
-0.010
-0.20%
已退市 09:30 07/24 EDT
开盘
4.930
昨收
4.930
最高
5.01
最低
4.880
成交量
896.68万
成交额
--
52周最高
7.16
52周最低
3.300
市值
2.41亿
市盈率(TTM)
-18.0882
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PETX 新闻

  • 美国安全部门批评优步去年车祸 存在"无效安全文化"
  • 新浪美股.6小时前
  • 特朗普再度召见鲍威尔 却没谈这个问题?
  • 参考消息网.7小时前
  • 全球最新城市实力排名出炉 伦敦连续8年当选世界第一
  • 新浪财经-自媒体综合.7小时前
  • 拍拍贷大跌至纪录低点 第三季财报显示增长乏力
  • 新浪美股.7小时前

更多

所属板块

制药
+0.40%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

PETX 简况

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.
展开

Webull提供Aratana Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。